Febuxostat 80mg 1 Film Coated Tablet [Prescription Required]

Indication: Treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or
presence of, tophus and/or gouty arthritis).
Contraindication: Hypersensitivity to Febuxostat (Feburic®,) or to any of the excipients listed in List of excipients

Place of Origin

Patheon, France

Product Usage

The recommended oral dose of Febuxostat (Feburic®) is 80 mg once daily without regard to food. If serum uric acid is > 6 mg/dL (357 μmol/L) after 2-4 weeks, the dose of 120 mg once daily may be considered.
Febuxostat (Feburic®) works sufficiently quickly to allow retesting of the serum uric acid after 2 weeks. The therapeutic target is to decrease and maintain serum uric acid below 6 mg/dL (357 μmol/L).
Gout flare prophylaxis of at least 6 months is recommended

Ingredients

List of excipients
Tablet core : Lactose monohydrate, Microcrystalline cellulose, Magnesium stearate, Hydroxypropylcellulose,
Croscarmellose sodium, Silica, colloidal hydrated
Tablet coating : Opadry II, Yellow, 85F42129 containing: Polyvinyl alcohol, Titanium dioxide (E171),
Macrogols 3350, Talc, Iron oxide yellow (E172)

Warnings

Not recommended use in patients w/ ischaemic heart disease or CHF & organ transplant recipients. Gout flares may occur during initiation of treatment; should be managed concurrently w/ appropriate treatment or prophylaxis for at least 6 mth w/ NSAID or colchicine is recommended. Patients w/ greatly increased rate of urate formation. Concomitant use w/ mercaptopurine/azathioprine is not recommended. Monitor closely for serious allergic/hypersensitivity reactions eg

Width

1

Height

1

Depth

1